We redefine the discovery and development of best-in-class oligonucleotide therapeutics. With our AI-empowered OligoCreator platform, which integrates a variety of delivery technologies, we identify and characterize oligonucleotide therapeutics with unparalleled speed and excellent safety and efficacy. By precisely delivering these novel therapeutics to specific cells, organs or tissues, targeted oligonucleotide therapies have the potential to revolutionize treatments for a wide range of difficult-to-treat disorders. Our unique OligoCreator platform is leveraged to transform untreatable conditions into treatable ones, profoundly changing the future of medicine.

With OligoCreator, we have built a unique oligonucleotide therapeutics discovery platform which has generated a diverse pipeline of innovative drug candidates, both proprietary and partnered, in various stages of pre-clinical and clinical development. Our focus is on targets where our oligonucleotide therapeutics have the potential to be first-in-class or best-in-class. We aim to improve patients’ lives by developing innovative solutions that address unmet medical needs and have the potential to offer superior outcomes.